<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1063863c-05ba-4009-922e-b8c0ab0d485b,g:81c9bf35-a0e9-43e9-bdb9-7c0acdbb181c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:abus="http://www.tekmirapharm.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.tekmirapharm.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.tekmirapharm.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.tekmirapharm.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofStockholdersEquity" roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementofStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statement of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.tekmirapharm.com/role/Organization">
        <link:definition>0000008 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significantaccountingpolicies" roleURI="http://www.tekmirapharm.com/role/Significantaccountingpolicies">
        <link:definition>0000009 - Disclosure - Significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurements" roleURI="http://www.tekmirapharm.com/role/Fairvaluemeasurements">
        <link:definition>0000010 - Disclosure - Fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investmentsinmarketablesecurities" roleURI="http://www.tekmirapharm.com/role/Investmentsinmarketablesecurities">
        <link:definition>0000011 - Disclosure - Investments in marketable securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinGenevant" roleURI="http://www.tekmirapharm.com/role/InvestmentinGenevant">
        <link:definition>0000012 - Disclosure - Investment in Genevant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.tekmirapharm.com/role/Leases">
        <link:definition>0000013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyandequipment" roleURI="http://www.tekmirapharm.com/role/Propertyandequipment">
        <link:definition>0000014 - Disclosure - Property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accountspayableandaccruedliabilities" roleURI="http://www.tekmirapharm.com/role/Accountspayableandaccruedliabilities">
        <link:definition>0000015 - Disclosure - Accounts payable and accrued liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Saleoffutureroyalties" roleURI="http://www.tekmirapharm.com/role/Saleoffutureroyalties">
        <link:definition>0000016 - Disclosure - Sale of future royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingenciesandcommitments" roleURI="http://www.tekmirapharm.com/role/Contingenciesandcommitments">
        <link:definition>0000017 - Disclosure - Contingencies and commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Collaborationsandroyaltyentitlements" roleURI="http://www.tekmirapharm.com/role/Collaborationsandroyaltyentitlements">
        <link:definition>0000018 - Disclosure - Collaborations and royalty entitlements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Shareholdersequity" roleURI="http://www.tekmirapharm.com/role/Shareholdersequity">
        <link:definition>0000019 - Disclosure - Shareholders&#8217; equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockbasedcompensation" roleURI="http://www.tekmirapharm.com/role/Stockbasedcompensation">
        <link:definition>0000020 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://www.tekmirapharm.com/role/Incometaxes">
        <link:definition>0000021 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Relatedpartytransactions" roleURI="http://www.tekmirapharm.com/role/Relatedpartytransactions">
        <link:definition>0000022 - Disclosure - Related party transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesPolicies" roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesPolicies">
        <link:definition>0000023 - Disclosure - Significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesTables" roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesTables">
        <link:definition>0000024 - Disclosure - Significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsTables" roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsTables">
        <link:definition>0000025 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinmarketablesecuritiesTables" roleURI="http://www.tekmirapharm.com/role/InvestmentsinmarketablesecuritiesTables">
        <link:definition>0000026 - Disclosure - Investments in marketable securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.tekmirapharm.com/role/LeasesTables">
        <link:definition>0000027 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandequipmentTables" roleURI="http://www.tekmirapharm.com/role/PropertyandequipmentTables">
        <link:definition>0000028 - Disclosure - Property and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountspayableandaccruedliabilitiesTables" roleURI="http://www.tekmirapharm.com/role/AccountspayableandaccruedliabilitiesTables">
        <link:definition>0000029 - Disclosure - Accounts payable and accrued liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleoffutureroyaltiesTables" roleURI="http://www.tekmirapharm.com/role/SaleoffutureroyaltiesTables">
        <link:definition>0000030 - Disclosure - Sale of future royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandroyaltyentitlementsTables" roleURI="http://www.tekmirapharm.com/role/CollaborationsandroyaltyentitlementsTables">
        <link:definition>0000031 - Disclosure - Collaborations and royalty entitlements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationTables" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationTables">
        <link:definition>0000032 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesTables" roleURI="http://www.tekmirapharm.com/role/IncometaxesTables">
        <link:definition>0000033 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.tekmirapharm.com/role/OrganizationDetails">
        <link:definition>0000034 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesNarrativeDetails">
        <link:definition>0000035 - Disclosure - Significant accounting policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesEstimatedusefullivesofpropertyandequipmentDetails" roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesEstimatedusefullivesofpropertyandequipmentDetails">
        <link:definition>0000036 - Disclosure - Significant accounting policies - Estimated useful lives of property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesComputationofbasicanddilutednetincomelosspercommonshareDetails" roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesComputationofbasicanddilutednetincomelosspercommonshareDetails">
        <link:definition>0000037 - Disclosure - Significant accounting policies - Computation of basic and diluted net income (loss) per common share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsNarrativeDetails">
        <link:definition>0000038 - Disclosure - Fair value measurements&#160; - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsAssetsandliabilitiesmeasuredatfairvalueonrecurringbasisDetails" roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsAssetsandliabilitiesmeasuredatfairvalueonrecurringbasisDetails">
        <link:definition>0000039 - Disclosure - Fair value measurements&#160; - Assets and liabilities measured at fair value on recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsChangesinfairvalueofliabilitiesclassifiedasstockoptionDetails" roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsChangesinfairvalueofliabilitiesclassifiedasstockoptionDetails">
        <link:definition>0000040 - Disclosure - Fair value measurements&#160; - Changes in fair value of liabilities - classified as stock option (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsChangesinfairvalueofcontingentconsiderationDetails" roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsChangesinfairvalueofcontingentconsiderationDetails">
        <link:definition>0000041 - Disclosure - Fair value measurements&#160;- Changes in fair value of contingent consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinmarketablesecuritiesDetails" roleURI="http://www.tekmirapharm.com/role/InvestmentsinmarketablesecuritiesDetails">
        <link:definition>0000042 - Disclosure - Investments in marketable securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinGenevantDetails" roleURI="http://www.tekmirapharm.com/role/InvestmentinGenevantDetails">
        <link:definition>0000043 - Disclosure - Investment in Genevant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/LeasesNarrativeDetails">
        <link:definition>0000044 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasecostDetails" roleURI="http://www.tekmirapharm.com/role/LeasesLeasecostDetails">
        <link:definition>0000045 - Disclosure - Leases - Lease cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofleaseliabilityDetails" roleURI="http://www.tekmirapharm.com/role/LeasesMaturityofleaseliabilityDetails">
        <link:definition>0000046 - Disclosure - Leases - Maturity of lease liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofleaseliabilityDetails_1" roleURI="http://www.tekmirapharm.com/role/LeasesMaturityofleaseliabilityDetails_1">
        <link:definition>0000046 - Disclosure - Leases - Maturity of lease liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandequipmentDetails" roleURI="http://www.tekmirapharm.com/role/PropertyandequipmentDetails">
        <link:definition>0000047 - Disclosure - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountspayableandaccruedliabilitiesDetails" roleURI="http://www.tekmirapharm.com/role/AccountspayableandaccruedliabilitiesDetails">
        <link:definition>0000048 - Disclosure - Accounts payable and accrued liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleoffutureroyaltiesNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/SaleoffutureroyaltiesNarrativeDetails">
        <link:definition>0000049 - Disclosure - Sale of future royalties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleoffutureroyaltiesActivityDetails" roleURI="http://www.tekmirapharm.com/role/SaleoffutureroyaltiesActivityDetails">
        <link:definition>0000050 - Disclosure - Sale of future royalties - Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsDetails" roleURI="http://www.tekmirapharm.com/role/ContingenciesandcommitmentsDetails">
        <link:definition>0000051 - Disclosure - Contingencies and commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandroyaltyentitlementsNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/CollaborationsandroyaltyentitlementsNarrativeDetails">
        <link:definition>0000052 - Disclosure - Collaborations and royalty entitlements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandroyaltyentitlementsSummaryofrevenuesDetails" roleURI="http://www.tekmirapharm.com/role/CollaborationsandroyaltyentitlementsSummaryofrevenuesDetails">
        <link:definition>0000053 - Disclosure - Collaborations and royalty entitlements - Summary of revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityDetails" roleURI="http://www.tekmirapharm.com/role/ShareholdersequityDetails">
        <link:definition>0000054 - Disclosure - Shareholders&#8217; equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationNarrativeDetails">
        <link:definition>0000055 - Disclosure - Stock-based compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationStockoptionactivityundertheArbutusPlanDetails" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationStockoptionactivityundertheArbutusPlanDetails">
        <link:definition>0000056 - Disclosure - Stock-based compensation - Stock option activity under the Arbutus Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationStockoptionsoutstandingundertheArbutusPlanDetails" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationStockoptionsoutstandingundertheArbutusPlanDetails">
        <link:definition>0000057 - Disclosure - Stock-based compensation - Stock options outstanding under the Arbutus Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationValuationassumptionsforstockoptionsundertheArbutusPlanDetails" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationValuationassumptionsforstockoptionsundertheArbutusPlanDetails">
        <link:definition>0000058 - Disclosure - Stock-based compensation - Valuation assumptions for stock options under the Arbutus Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationStockoptionactivityforliabilityclassifiedoptionsDetails" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationStockoptionactivityforliabilityclassifiedoptionsDetails">
        <link:definition>0000059 - Disclosure - Stock-based compensation - Stock option activity for liability-classified options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationOutstandingoptionsundertheOncoreOptionPlanDetails" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationOutstandingoptionsundertheOncoreOptionPlanDetails">
        <link:definition>0000060 - Disclosure - Stock-based compensation - Outstanding options under the Oncore Option Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationStockbasedcompensationexpenseDetails" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationStockbasedcompensationexpenseDetails">
        <link:definition>0000061 - Disclosure - Stock-based compensation - Stock-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/IncometaxesNarrativeDetails">
        <link:definition>0000062 - Disclosure - Income taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesIncometaxreconciliationDetails" roleURI="http://www.tekmirapharm.com/role/IncometaxesIncometaxreconciliationDetails">
        <link:definition>0000063 - Disclosure - Income taxes - Income tax reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesDeferredtaxassetsandliabilitiesDetails" roleURI="http://www.tekmirapharm.com/role/IncometaxesDeferredtaxassetsandliabilitiesDetails">
        <link:definition>0000064 - Disclosure - Income taxes - Deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartytransactionsDetails" roleURI="http://www.tekmirapharm.com/role/RelatedpartytransactionsDetails">
        <link:definition>0000065 - Disclosure - Related party transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="abus_ArbutusInc.Member" abstract="true" name="ArbutusInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_NonCashRoyaltyMember" abstract="true" name="NonCashRoyaltyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" abstract="false" name="EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" abstract="false" name="LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_GrossProceedsFromRoyaltyInterestSold" abstract="false" name="GrossProceedsFromRoyaltyInterestSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_IncomeTaxesDetailsLineItems" abstract="true" name="IncomeTaxesDetailsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_DeferredTaxAssetBookAmortizationInExcessOfTax" abstract="false" name="DeferredTaxAssetBookAmortizationInExcessOfTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_AnnualRevenueThreshold" abstract="false" name="AnnualRevenueThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_DeferredTaxAssetsLiabilitiesGross" abstract="false" name="DeferredTaxAssetsLiabilitiesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" abstract="false" name="LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_OtherMilestonesAndRoyaltyPaymentsMember" abstract="true" name="OtherMilestonesAndRoyaltyPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" abstract="false" name="LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_AlnylamEntitlements" abstract="false" name="AlnylamEntitlements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abus_JefferiesLLCMember" abstract="true" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_RoyaltyPayable" abstract="false" name="RoyaltyPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_ComponentsofDeferredTaxAssetsTable" abstract="true" name="ComponentsofDeferredTaxAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abus_NumberOfWhollyOwnedSubsidiaries" abstract="false" name="NumberOfWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abus_RoyaltyPercentageofInterestSold" abstract="false" name="RoyaltyPercentageofInterestSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_RoivantSciencesLtdMember" abstract="true" name="RoivantSciencesLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abus_Aug2020ProspectusSupplementMember" abstract="true" name="Aug2020ProspectusSupplementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ChangesInFairValueofLiabilityOptionTableTextBlock" abstract="false" name="ChangesInFairValueofLiabilityOptionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" abstract="false" name="ArbitrationWithTheUniversityOfBritishColumbiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_EmployeeStockOptionLiabilityClassifiedMember" abstract="true" name="EmployeeStockOptionLiabilityClassifiedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_USCorporateBondsMember" abstract="true" name="USCorporateBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" abstract="false" name="AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="abus_AdministrativeAndTransitionalServicesMember" abstract="true" name="AdministrativeAndTransitionalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OtherLiabilitiesDisclosureLineItems" abstract="true" name="OtherLiabilitiesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" abstract="false" name="LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abus_Nov2021RegistrationStmtMember" abstract="true" name="Nov2021RegistrationStmtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_March2022ProspectusSupplementMember" abstract="true" name="March2022ProspectusSupplementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement" abstract="false" name="ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_Oct2020RegistrationStmtMember" abstract="true" name="Oct2020RegistrationStmtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_DirectorsAndExecutivesMember" abstract="true" name="DirectorsAndExecutivesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_NonvestedMember" abstract="true" name="NonvestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_CollierPlanMember" abstract="true" name="CollierPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_StockIssuedDuringPeriodValueNewIssuesSharePurchaseAgreement" abstract="false" name="StockIssuedDuringPeriodValueNewIssuesSharePurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_RoyaltyGuaranteesCommitmentsPercentage" abstract="false" name="RoyaltyGuaranteesCommitmentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" abstract="true" name="FairValueLiabilitiesMeasuredonRecurringBasisRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_CollaborationAndContractsMember" abstract="true" name="CollaborationAndContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember" abstract="true" name="CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_VestedMember" abstract="true" name="VestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_USGovernmentAgencyBondsMember" abstract="true" name="USGovernmentAgencyBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_SubLicensingRevenuePercentage" abstract="false" name="SubLicensingRevenuePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_QiluPharmaceuticalCoLTDMember" abstract="true" name="QiluPharmaceuticalCoLTDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_RoyaltyInterestPercentInterest" abstract="false" name="RoyaltyInterestPercentInterest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_XChemIncAndProterosMember" abstract="true" name="XChemIncAndProterosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_AccruedResearchandDevelopmentCurrent" abstract="false" name="AccruedResearchandDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_VaccitechMember" abstract="true" name="VaccitechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes" abstract="false" name="DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember" abstract="true" name="OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_USGovernmentBondsMember" abstract="true" name="USGovernmentBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LesseeOperatingLeaseNumberofLeases" abstract="false" name="LesseeOperatingLeaseNumberofLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abus_LongTermInvestmentsMember" abstract="true" name="LongTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OpenMarketSaleAgreementMember" abstract="true" name="OpenMarketSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_EffectiveAnnualInterestRateOfRoyaltyLiability" abstract="false" name="EffectiveAnnualInterestRateOfRoyaltyLiability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abus_ContingenciesandCommitmentsTable" abstract="true" name="ContingenciesandCommitmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abus_AccruedPayrollCurrent" abstract="false" name="AccruedPayrollCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_EffectiveIncomeTaxRateReconciliationTaxWithholding" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_ONPATTROGlobalNetSalesMember" abstract="true" name="ONPATTROGlobalNetSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_FixedLeaseCost" abstract="false" name="FixedLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_EnantigensSellingShareholdersMember" abstract="true" name="EnantigensSellingShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" abstract="false" name="LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_StockIssuedDuringPeriodSharesNewIssuesSharePurchaseAgreement" abstract="false" name="StockIssuedDuringPeriodSharesNewIssuesSharePurchaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abus_BlumbergandDrexelMember" abstract="true" name="BlumbergandDrexelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer" abstract="false" name="RoyaltyInterestSoldMaximumRoyaltiesForBuyer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" abstract="false" name="IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_LiabilityRelatedToFutureRoyaltiesRollForward" abstract="true" name="LiabilityRelatedToFutureRoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_OMERSMember" abstract="true" name="OMERSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OneTimeUpfrontCashPaymentMember" abstract="true" name="OneTimeUpfrontCashPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_StockIssuedDuringPeriodSharesNewIssuesOpenMarketSaleAgreement" abstract="false" name="StockIssuedDuringPeriodSharesNewIssuesOpenMarketSaleAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abus_AssemblyBiosciencesIncMember" abstract="true" name="AssemblyBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OnpattroNonCashRoyaltyMember" abstract="true" name="OnpattroNonCashRoyaltyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements" abstract="false" name="DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_ContingenciesandCommitmentsLineItems" abstract="true" name="ContingenciesandCommitmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_RegistrationStatementAxis" abstract="true" name="RegistrationStatementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abus_QiluMember" abstract="true" name="QiluMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OnCoreOptionPlanMember" abstract="true" name="OnCoreOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement" abstract="false" name="StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_PremiumonClosingStockPrice" abstract="false" name="PremiumonClosingStockPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_ProceedsFromIssuanceOfCommonStockSharePurchaseAgreement" abstract="false" name="ProceedsFromIssuanceOfCommonStockSharePurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_BonaFideCollaborationPercentage" abstract="false" name="BonaFideCollaborationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_CommonStockDiscountOnSharesPercentage" abstract="false" name="CommonStockDiscountOnSharesPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember" abstract="true" name="Jan2020Oct2020AndNov2021RegistrationStmtsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_Jan2020ProspectusSupplementMember" abstract="true" name="Jan2020ProspectusSupplementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LaboratoryEquipmentMember" abstract="false" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" abstract="false" name="LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_RegistrationStatementDomain" abstract="true" name="RegistrationStatementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LicenseAgreementMilestonePaymentMaximum" abstract="false" name="LicenseAgreementMilestonePaymentMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" abstract="false" name="LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abus_ComponentsofDeferredTaxAssetsLineItems" abstract="true" name="ComponentsofDeferredTaxAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_October2021ProspectusSupplementMember" abstract="true" name="October2021ProspectusSupplementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_EnantigenMember" abstract="false" name="EnantigenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" abstract="false" name="RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_Mar2021ProspectusSupplementAgreementMember" abstract="true" name="Mar2021ProspectusSupplementAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_PercentOfCostsRelatedToCollaboration" abstract="false" name="PercentOfCostsRelatedToCollaboration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_ArbutusPlansMember" abstract="true" name="ArbutusPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OnpattroCashRoyaltyMember" abstract="true" name="OnpattroCashRoyaltyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_A2016And2011PlansMember" abstract="true" name="A2016And2011PlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_TransactionCostsRelatedToSaleOfFutureRoyalties" abstract="false" name="TransactionCostsRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_Jan2020RegistrationStmtMember" abstract="true" name="Jan2020RegistrationStmtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_EquityMethodInvestmentPercentageOfRevenueEntitled" abstract="false" name="EquityMethodInvestmentPercentageOfRevenueEntitled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" abstract="false" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abus_GenevantSciencesCorporationMember" abstract="true" name="GenevantSciencesCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_WeightedAverageNumberOfCommonSharesAbstract" abstract="true" name="WeightedAverageNumberOfCommonSharesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" abstract="false" name="NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
